BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 35728703)

  • 1. Identification of structurally re-engineered rocaglates as inhibitors against hepatitis E virus replication.
    Praditya DF; Klöhn M; Brüggemann Y; Brown LE; Porco JA; Zhang W; Kinast V; Kirschning A; Vondran FWR; Todt D; Steinmann E
    Antiviral Res; 2022 Aug; 204():105359. PubMed ID: 35728703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo.
    Todt D; Moeller N; Praditya D; Kinast V; Friesland M; Engelmann M; Verhoye L; Sayed IM; Behrendt P; Dao Thi VL; Meuleman P; Steinmann E
    Antiviral Res; 2018 Sep; 157():151-158. PubMed ID: 30036559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribavirin Treatment Failure-Associated Mutation, Y1320H, in the RNA-Dependent RNA Polymerase of Genotype 3 Hepatitis E Virus (HEV) Enhances Virus Replication in a Rabbit HEV Infection Model.
    Wang B; Mahsoub HM; Li W; Heffron CL; Tian D; Hassebroek AM; LeRoith T; Meng XJ
    mBio; 2023 Apr; 14(2):e0337222. PubMed ID: 36809085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication.
    Todt D; François C; Anggakusuma ; Behrendt P; Engelmann M; Knegendorf L; Vieyres G; Wedemeyer H; Hartmann R; Pietschmann T; Duverlie G; Steinmann E
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2132-9. PubMed ID: 26787701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Requirement of the eukaryotic translation initiation factor 4F complex in hepatitis E virus replication.
    Zhou X; Xu L; Wang Y; Wang W; Sprengers D; Metselaar HJ; Peppelenbosch MP; Pan Q
    Antiviral Res; 2015 Dec; 124():11-9. PubMed ID: 26526587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral candidates against the hepatitis E virus (HEV) and their combinations inhibit HEV growth in in vitro.
    Nishiyama T; Kobayashi T; Jirintai S; Nagashima S; Primadharsini PP; Nishizawa T; Okamoto H
    Antiviral Res; 2019 Oct; 170():104570. PubMed ID: 31362004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral Candidates for Treating Hepatitis E Virus Infection.
    Netzler NE; Enosi Tuipulotu D; Vasudevan SG; Mackenzie JM; White PA
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30885901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zinc Salts Block Hepatitis E Virus Replication by Inhibiting the Activity of Viral RNA-Dependent RNA Polymerase.
    Kaushik N; Subramani C; Anang S; Muthumohan R; Shalimar ; Nayak B; Ranjith-Kumar CT; Surjit M
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28814517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive Regulation of Hepatitis E Virus Replication by MicroRNA-122.
    Haldipur B; Bhukya PL; Arankalle V; Lole K
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Robust hepatitis E virus infection and transcriptional response in human hepatocytes.
    Todt D; Friesland M; Moeller N; Praditya D; Kinast V; Brüggemann Y; Knegendorf L; Burkard T; Steinmann J; Burm R; Verhoye L; Wahid A; Meister TL; Engelmann M; Pfankuche VM; Puff C; Vondran FWR; Baumgärtner W; Meuleman P; Behrendt P; Steinmann E
    Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1731-1741. PubMed ID: 31896581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (-) and the eIF4A-inhibitor Silvestrol.
    Müller C; Obermann W; Schulte FW; Lange-Grünweller K; Oestereich L; Elgner F; Glitscher M; Hildt E; Singh K; Wendel HG; Hartmann RK; Ziebuhr J; Grünweller A
    Antiviral Res; 2020 Mar; 175():104706. PubMed ID: 31931103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dose sofosbuvir and sofosbuvir-plus-ribavirin therapy inhibit Hepatitis E Virus (HEV) replication in a rabbit model for acute HEV infection.
    Liang Z; Shu J; He Q; Zhang F; Dai L; Wang L; Lu F; Wang L
    Antiviral Res; 2022 Mar; 199():105274. PubMed ID: 35247472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus.
    Wang Y; Zhou X; Debing Y; Chen K; Van Der Laan LJ; Neyts J; Janssen HL; Metselaar HJ; Peppelenbosch MP; Pan Q
    Gastroenterology; 2014 Jun; 146(7):1775-83. PubMed ID: 24582714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication.
    Wang W; Wang Y; Debing Y; Zhou X; Yin Y; Xu L; Herrera Carrillo E; Brandsma JH; Poot RA; Berkhout B; Neyts J; Peppelenbosch MP; Pan Q
    Antiviral Res; 2017 Apr; 140():1-12. PubMed ID: 28077314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon.
    Debing Y; Emerson SU; Wang Y; Pan Q; Balzarini J; Dallmeier K; Neyts J
    Antimicrob Agents Chemother; 2014; 58(1):267-73. PubMed ID: 24145541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection.
    Zhou X; Xu L; Wang W; Watashi K; Wang Y; Sprengers D; de Ruiter PE; van der Laan LJ; Metselaar HJ; Kamar N; Peppelenbosch MP; Pan Q
    J Viral Hepat; 2016 Apr; 23(4):294-304. PubMed ID: 26620360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug repurposing screen identifies vidofludimus calcium and pyrazofurin as novel chemical entities for the development of hepatitis E interventions.
    Guo H; Liu D; Liu K; Hou Y; Li C; Li Q; Ding X; Verstegen MMA; Zhang J; Wang L; Ding Y; Tang R; Pan X; Zheng K; van der Laan LJW; Pan Q; Wang W
    Virol Sin; 2024 Feb; 39(1):123-133. PubMed ID: 37984761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication.
    Wang Y; Wang W; Xu L; Zhou X; Shokrollahi E; Felczak K; van der Laan LJ; Pankiewicz KW; Sprengers D; Raat NJ; Metselaar HJ; Peppelenbosch MP; Pan Q
    Antimicrob Agents Chemother; 2016 May; 60(5):2834-48. PubMed ID: 26926637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis E virus treatment and ribavirin therapy: viral mechanisms of nonresponse.
    Todt D; Meister TL; Steinmann E
    Curr Opin Virol; 2018 Oct; 32():80-87. PubMed ID: 30384328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutagenic Effects of Ribavirin on Hepatitis E Virus-Viral Extinction versus Selection of Fitness-Enhancing Mutations.
    Todt D; Walter S; Brown RJ; Steinmann E
    Viruses; 2016 Oct; 8(10):. PubMed ID: 27754363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.